West Pharmaceutical Services Inc
NYSE:WST
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
277.16
413
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
West Pharmaceutical Services Inc
Intrinsic Value
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. [ Read More ]
The intrinsic value of one
WST
stock under the Base Case scenario is
236.4
USD.
Compared to the current market price of 284.76 USD,
West Pharmaceutical Services Inc
is
Overvalued by 17%.
West Pharmaceutical Services Inc's market capitalization is 20.8B USD.
WST stock price is 284.76 USD.
WST stock (236.4 USD) is 17% less than its price (284.76 USD).
WST stock price (284.76 USD) is 16% less than its Relative Value (338.89 USD). Open Relative Valuation
WST has upside potential of 43% compared to the average analyst price target.
Open Wall St Estimates
WST's Revenue has grown by 0% over the past 12 months.
WST's Revenue has been growing by 4% per year for the last 3 years.
WST's Revenue is forecast to grow at a rate of 7% per year over the next 3 years.
WST's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 18%.
WST's ROE (Return on Equity) for the past 12 months is positive and is equal to 19%.
WST's ROIC (Return on Invested Capital) has decreased in the last 3 years from 26% to 18%.
WST's ROE (Return on Equity) has decreased in the last 3 years from 29% to 19%.
WST has positive Net Income for the last twelve months.
WST has positive Operating Income for the last twelve months.
WST has positive Free Cash Flow for the last twelve months.
WST has positive Gross Profit for the last twelve months.
WST has positive three-year average ROE (Return on Equity): 25%. The company is efficient at transforming stockholders' equity into net income.
WST has positive three-year average ROIC (Return on Invested Capital): 25%. The company is efficient at using invested capital to generate operating income.
WST's short-term assets (2B USD) exceed its short-term liabilties (648m USD).
WST's long-term assets (4B USD) exceed its long-term liabilties (922m USD).
WST's D/E (Debt to Equity) is very low and is equal to 0.03.
WST has negative Net Debt. This means that the company has more cash and short-term investments (602m USD) than debt (73m USD).
WST's Altman Z-Score is very high and is equal to 18.55.
Valuation Backtest
West Pharmaceutical Services Inc
Run backtest to discover the historical profit from buying and selling
WST
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
West Pharmaceutical Services Inc
| Current Assets | 1.7B |
| Cash & Short-Term Investments | 601.8m |
| Receivables | 524m |
| Other Current Assets | 567.1m |
| Non-Current Assets | 1.9B |
| Long-Term Investments | 202.5m |
| PP&E | 1.5B |
| Intangibles | 121.5m |
| Other Non-Current Assets | 40m |
| Current Liabilities | 648.4m |
| Accounts Payable | 240.1m |
| Accrued Liabilities | 84.5m |
| Other Current Liabilities | 323.8m |
| Non-Current Liabilities | 273.3m |
| Long-Term Debt | 72.8m |
| Other Non-Current Liabilities | 200.5m |
Earnings Waterfall
West Pharmaceutical Services Inc
|
Revenue
|
2.9B
USD
|
|
Cost of Revenue
|
-1.9B
USD
|
|
Gross Profit
|
1B
USD
|
|
Operating Expenses
|
-439.5m
USD
|
|
Operating Income
|
587.2m
USD
|
|
Other Expenses
|
-62.3m
USD
|
|
Net Income
|
524.9m
USD
|
Free Cash Flow Analysis
West Pharmaceutical Services Inc
| USD | |
| Free Cash Flow | USD |
WST Profitability Score
Profitability Due Diligence
West Pharmaceutical Services Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
West Pharmaceutical Services Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
WST Solvency Score
Solvency Due Diligence
West Pharmaceutical Services Inc's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Score
West Pharmaceutical Services Inc's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
WST Price Targets Summary
West Pharmaceutical Services Inc
According to Wall Street analysts, the average 1-year price target for
WST
is 407.62 USD
with a low forecast of 358.55 USD and a high forecast of 493.5 USD.
Click here to dive deeper.
Ownership
WST Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Price Appreciation
WST Price
West Pharmaceutical Services Inc
| Average Annual Return | 26.94% |
| Standard Deviation of Annual Returns | 59.17% |
| Max Drawdown | -56% |
| Market Capitalization | 20.8B USD |
| Shares Outstanding | 72 840 000 |
| Percentage of Shares Shorted | 2.21% |
Company Profile
West Pharmaceutical Services Inc
Country
Industry
Market Cap
Dividend Yield
Description
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. The company is headquartered in Exton, Pennsylvania and currently employs 10,065 full-time employees. The firm operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
Contact
IPO
Employees
Officers
The intrinsic value of one
WST
stock under the Base Case scenario is
236.4
USD.
Compared to the current market price of 284.76 USD,
West Pharmaceutical Services Inc
is
Overvalued by 17%.
You don't have any saved screeners yet
